Cell Therapy in the Treatment of Female Stress Urinary Incontinence: Current Status and Future Proposals
González Enguita C., Garranzo García-Ibarrola M., Tufet I Jaumont JJ., Garde García H., González López R., Quintana Franco LM.
Clinical Trial, published in Life (Basel) (2024) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Life (Basel) (2024)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 39063615
- PMCID
- PMC11278173
- DOI
- 10.3390/life14070861
- Citations
- 1
Abstract (original English)
Background Stress urinary incontinence (SUI) is a common condition with a significant impact on the quality of life of female patients. The limitations of current treatment strategies have prompted the exploration of new effective and minimally invasive alternative approaches, including cell therapy. Methods A literature search was conducted to update the current clinical status of stem cell therapy in the management of female stress urinary incontinence. Results Over thirty clinical studies have been designed to assess the feasibility, safety and efficacy of cell therapy for female SUI. Despite differences in cell types and protocols, the overall treatment procedures were similar. Standard subjective and objective assessment tools, and follow-up periods ranged from 6 weeks to 6 years have been used. Cell injection has shown to be a safe therapy in the treatment of female SUI. However, the results from more recent randomized trials have shown less promising results than expected in restoring continence. Heterogeneous research methodologies using different cell types and doses make it difficult to draw conclusions about effectiveness. Several key points remain that need to be further explored in future clinical trials. Conclusion To advance in the development of cell therapy, it is essential to know the mechanisms involved to be able to direct it properly, its efficacy and the d
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.